Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Fluticasone furoate, umeclidinium, and vilanterol

(Trelegy Ellipta®)

Trelegy Ellipta®

Drug updated on 9/5/2024

Dosage FormPowder (inhalation; fluticasone furoate/ umeclidinium/ vilanterol; 100/62.5/25 mcg); Powder (inhalation; fluticasone furoate/ umeclidinium/ vilanterol; 200/62.5/25 mcg)
Drug ClassCorticosteroid, anticholinergic and long-acting beta2-adrenergic agonists
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
  • Indicated for the maintenance treatment of asthma in patients aged 18 years and older.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 18 years and older.
  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • At 24 weeks, FF/UMEC/VI was significantly more effective in increasing trough FEV1 compared to all triple therapy comparators except UMEC + FF/VI.
  • FF/UMEC/VI demonstrated statistically significant improvements in the annualized rate of combined moderate and severe exacerbations compared to BUD/GLY/FOR and UMEC + FF/VI at 24 weeks.
  • A network meta-analysis indicated no statistically significant differences in effectiveness outcomes, including exacerbation rate, FEV1, SGRQ score, and rescue medication use, between BGF MDI and other ICS/LAMA/LABA fixed-dose combinations, such as FF/UMEC/VI.
  • There is no safety information available in the reviewed studies.
  • There is no population types or subgroups information available in the reviewed studies.